Request Demo

Last update 27 Feb 2026

Memantine hydrochloride

Last update 27 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

memantine, Memantine hydrochloride oral dissolving film (Heze Pharmaceutical), Memantine hydrochloride (JAN/USP)

+ [23]

Target

NMDA receptor

Action

antagonists

Mechanism

NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesImmune System Diseases+ [1]

Active Indication

Alzheimer DiseaseDementiaCognitive Dysfunction+ [1]

Inactive Indication

AggressionAgitationAmyotrophic Lateral Sclerosis+ [25]

Originator Organization

Merz Pharma GmbH & Co. KGaA

Active Organization

KRKA dd

Libbs Farmacêutica Ltda.

AbbVie, Inc.

+ [11]

Inactive Organization

Forest Laboratories LLC

Mylan NV

Pharmathen SA

+ [7]

License Organization

H. Lundbeck A/S

Daewoong Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Germany (11 Aug 2000),

Dementia

Regulation-

Structure/Sequence

Molecular FormulaC12H22ClN

InChIKeyLDDHMLJTFXJGPI-UHFFFAOYSA-N

CAS Registry41100-52-1

404

Clinical Trials associated with Memantine hydrochloride

NCT07248228

/ Not yet recruitingPhase 2IIT

A Randomized Phase 2 Trial of Memory Avoidance Whole Brain Radiotherapy Versus Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve cognitive function. This study compares that approach to another approach of whole brain radiotherapy that stays away from additional structures that are thought to have a role in cognitive function. Researchers want to see if there is a difference in the preservation of cognitive function between these two approaches.

Start Date01 Mar 2026

Sponsor / Collaborator

The Case Comprehensive Cancer Center

NCT07139834

/ Not yet recruitingPhase 1IIT

Examining the Effects of Escitalopram and Memantine on Pattern Separation in Major Depressive Disorder

This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.

Start Date01 Jan 2026

Sponsor / Collaborator

The New York State Psychiatric Institute

IRCT20211017052786N7

/ RecruitingPhase 3IIT

Comparing the effectiveness of memantine with routine treatment in the prognosis of acute stroke patients

Start Date21 Nov 2025

Sponsor / Collaborator-

100 Clinical Results associated with Memantine hydrochloride

100 Translational Medicine associated with Memantine hydrochloride

100 Patents (Medical) associated with Memantine hydrochloride

5,020

Literatures (Medical) associated with Memantine hydrochloride

01 May 2026·BRAIN BEHAVIOR AND IMMUNITY

Targeting α7nAChR-driven brain endothelial pyroptosis mitigates HIV-1 gp120-induced blood–brain barrier breakdown

Article

Author: Chen, Jingyu ; Huang, Pengwei ; Cao, Hong ; Zhou, Bingliang ; Chen, Jie ; Zou, Jinhu ; Gao, Xuefeng ; Meng, Xiangshun

HIV-1-associated neurocognitive disorder (HAND) persists in over 40% of people with HIV despite effective antiretroviral therapy, underscoring the absence of targeted interventions. Disruption of the blood-brain barrier (BBB) is a hallmark of HAND, yet the mechanisms that link viral proteins to endothelial injury remain insufficiently understood. This study demonstrates that the HIV-1 envelope glycoprotein gp120 induces pyroptosis of brain microvascular endothelial cells (BMECs), thereby compromising BBB integrity. This process is mediated by the α7 nicotinic acetylcholine receptor (α7nAChR)-dependent activation of the ROS/NF-κB/NLRP3 inflammasome axis. Unexpectedly, α7nAChR, typically regarded as anti-inflammatory, exhibits a paradoxical pathogenic role under HIV-1 gp120 exposure, driving inflammatory endothelial cell death rather than protection. Importantly, this detrimental pathway is effectively inhibited by two clinically approved drugs, memantine and metformin, through suppression of α7nAChR. These findings uncover endothelial pyroptosis as a previously unrecognized mechanism of gp120-induced BBB disruption, redefine the functional role of α7nAChR in HAND pathogenesis, and highlight a promising therapeutic strategy through drug repurposing. By revealing a targetable pathway with direct clinical applicability, this work provides mechanistic insights and translational opportunities for preserving BBB function in HIV-associated neuropathology.

01 Mar 2026·GERIATRIC NURSING

Examining pharmacological and demographic factors among male and female alzheimer’s disease patients diagnosed with attention concentration disorder and cognitive communication disorder

Article

Author: Nathaniel, Adebobola I ; Agbomi, Lidadi L ; Desai, Ashna ; Roley, Laurie Theriot ; Nathaniel, Thomas I ; Nathaniel, Emmanuel I ; Goodwin, Richard

OBJECTIVE:

This study examines the differences between male and female Alzheimer's Disease patients diagnosed with Attention Concentration Deficit (ADACD) and Cognitive Communicative Disorder (ADCCD), focusing on pharmacological and demographic factors.

METHOD:

A multivariate analysis was conducted to identify pharmacological and demographic factors associated with ADACD and ADCCD in male and female patients.

RESULTS:

In the adjusted analysis for male patients, use of donepezil (OR = 1.683, 95 % CI: 1.172-2.417, p = 0.005), and risperidone (Risperdal) use (OR = 3.177, 95 % CI: 1.841-5.484, p < 0.001) were significantly associated with ADCCD. The use of memantine (OR = 0.189, 95 % CI: 0.091-0.393, p < 0.001), aripiprazole (OR = 0.065, 95 % CI: 0.015-0.278, p < 0.001), were associated with ADACD. For female patients, citalopram use (OR = 2.470, 95 % CI: 1.751-3.484, p < 0.001) was associated with ADCCD.

CONCLUSION:

These results underscore the urgent need to establish strategies aimed at addressing sex disparities in the care of ADACD and ADCCD patients.

01 Mar 2026·CURRENT OPINION IN PSYCHIATRY

Apathy in dementia: pharmacological and nonpharmacological treatment strategies

Review

Author: Bilgiç, Başar ; Ince Guliyev, Ezgi ; Büyükgök, Deniz

Purpose of review:

Apathy is one of the most prevalent and disabling symptoms of neurodegenerative disorders, yet targeted treatments remain poorly defined. In recent years, growing interest in its conceptualization and management has led to an increasing number of randomized controlled trials (RCTs) and meta-analyses addressing both pharmacological and nonpharmacological interventions.

Recent findings:

Among pharmacological approaches, methylphenidate presented with early reductions in apathy with an acceptable safety profile in multiple RCTs, including a large 6-month trial. However, the sustainability of effect has not been fully achieved. Other stimulants, bupropion, and conventional Alzheimer's medications such as cholinesterase inhibitors and memantine show inconsistent or limited effects. Antidepressants and antipsychotics are not recommended for apathy, although selected agents may benefit comorbid conditions. As for the nonpharmacological interventions, evidence supports the benefits of physical exercise and the emerging promise of neuromodulation. Technology-based interventions are feasible but show variable efficacy.

Summary:

Methylphenidate currently represents the most studied pharmacological agent for apathy in Alzheimer's disease (AD). However, optimal management is likely to combine pharmacological and psychosocial strategies tailored to the patient context. Future studies should include pragmatic trials with apathy as a primary endpoint, long-term follow-up, and expansion beyond AD.

114

News (Medical) associated with Memantine hydrochloride

25 Feb 2026

·www.businesswire.com

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting. The BEACON study is designed to assess the real-world impact of ZUNVEYL on cognition, neuropsychiatric symptoms, safety, and tolerability in patients with Alzheimer’s disease residing in nursing homes. By generating data in routine clinical practice, the study aims to complement findings from earlier clinical trials and provide practice-relevant evidence in a care setting with significant unmet need that will further support the Company’s commercialization efforts. “Enrollment of first patient in the BEACON study represents a significant milestone for Alpha Cognition,” said Kurt Grady, Alpha Cognition’s Vice President of Medical Affairs. “This study is designed to generate real-world clinical evidence in the nursing home environment, where the need for effective and well-tolerated therapies is particularly high. If positive, these data have the potential to further strengthen the clinical foundation for ZUNVEYL and support our ongoing commercial launch by providing meaningful insights for healthcare providers, patients, and caregivers.” BEACON is a post-approval study expected to enroll approximately 200 patients across multiple clinical sites. The study will collect efficacy data and monitor adverse events throughout the study period, contributing to ongoing post-market evaluation and informing real-world clinical use of ZUNVEYL in the long-term care population. Alpha Cognition expects to report topline results in the fourth quarter of 2026, following completion of enrollment and patient follow-up. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements with the anticipated results of the BEACON study and the potential for such results to further strengthen the clinical foundation for ZUNVEYL and support its ongoing commercial launch, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K as filed with the SEC on May 31, 2025 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

Phase 2Phase 3

18 Feb 2026

·www.alphacognition.com

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL® Dosing Regimens

VANCOUVER, B.C. and GRAPEVINE, TX — February 18, 2026 — Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled “Dosage Regimens for Benzgalantamine.” The issued patent includes claims covering methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer’s disease using specific dosing regimens. The patent is expected to provide U.S. patent protection through July 2045 and represents an important addition to the Company’s intellectual property portfolio supporting ZUNVEYL, Alpha Cognition’s FDA-approved therapy for mild to moderate Alzheimer’s disease. “This newly issued patent meaningfully strengthens the intellectual property protection surrounding ZUNVEYL by covering clinically relevant dosing regimens for oral administration,” said Michael McFadden, Chief Executive Officer of Alpha Cognition. “These method-of-use claims extend and reinforce our existing patent portfolio, supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value in the U.S. market.” The issuance of this patent further advances Alpha Cognition’s long-term intellectual property strategy by protecting key methods of administering benzgalantamine and extending exclusivity beyond existing patent coverage. The Company believes this patent underscores the innovative nature of its benzgalantamine research and supports durable market protection for ZUNVEYL. About Alpha Cognition Inc. Alpha Cognition Inc. is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s expectation that the additional U.S. patent will provide U.S. patent protection through July 2045 and supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value and protecting key methods of administering benzgalantamine, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL , risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company’s intellectual property in relation to ZUNVEYL , risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL , risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K as filed with the SEC on March 31, 2025 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law. For further information: Investor Relations LifeSci Advisors, PJ Kelleher pkelleher@lifesciadvisors.com

Drug ApprovalPatent Expiration

18 Feb 2026

·www.biospace.com

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled “Dosage Regimens for Benzgalantamine.” The issued patent includes claims covering methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer’s disease using specific dosing regimens. The patent is expected to provide U.S. patent protection through July 2045 and represents an important addition to the Company’s intellectual property portfolio supporting ZUNVEYL, Alpha Cognition’s FDA-approved therapy for mild to moderate Alzheimer’s disease. “This newly issued patent meaningfully strengthens the intellectual property protection surrounding ZUNVEYL by covering clinically relevant dosing regimens for oral administration,” said Michael McFadden, Chief Executive Officer of Alpha Cognition. “These method-of-use claims extend and reinforce our existing patent portfolio, supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value in the U.S. market.” The issuance of this patent further advances Alpha Cognition’s long-term intellectual property strategy by protecting key methods of administering benzgalantamine and extending exclusivity beyond existing patent coverage. The Company believes this patent underscores the innovative nature of its benzgalantamine research and supports durable market protection for ZUNVEYL. About Alpha Cognition Inc. Alpha Cognition Inc. is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s expectation that the additional U.S. patent will provide U.S. patent protection through July 2045 and supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value and protecting key methods of administering benzgalantamine, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL , risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company’s intellectual property in relation to ZUNVEYL , risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL , risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K as filed with the SEC on March 31, 2025 and available at . These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law. Contacts Investor Relations LifeSci Advisors, PJ Kelleher pkelleher@lifesciadvisors.com

Drug ApprovalPatent Expiration

100 Deals associated with Memantine hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D04905	Memantine hydrochloride	N06DX01	DB01043

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	European Union	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	Iceland	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	Liechtenstein	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	Norway	H. Lundbeck A/S	15 May 2002
Dementia	Germany	H. Lundbeck A/S	11 Aug 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dementia, Vascular	Phase 3	Russia	Merz Pharmaceuticals GmbH	23 Jan 2018
Frontotemporal Dementia	Phase 3	Canada	H. Lundbeck A/S	01 Oct 2007
Dementia due to Parkinson's disease	Phase 3	Spain	H. Lundbeck A/S	22 Dec 2006
Lewy Body Disease	Phase 3	Austria	H. Lundbeck A/S	22 Sep 2006
Progressive Supranuclear Palsy Atypical	Phase 3	Austria	H. Lundbeck A/S	22 Sep 2006
Multiple Sclerosis, Relapsing-Remitting	Phase 3	France	H. Lundbeck A/S	01 Sep 2005
Amyotrophic Lateral Sclerosis	Phase 3	Portugal	H. Lundbeck A/S	01 Jul 2005
Agitation	Phase 3	United States	Forest Laboratories LLC	01 Sep 2004
Cognitive Dysfunction	Phase 3	United States	Forest Laboratories LLC	01 Apr 2004
Multiple Sclerosis	Phase 3	United States	Forest Laboratories LLC	01 Apr 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03703856 (CTgov)	Phase 4	Alzheimer Disease	53	Memantine	xnuspjnrmg(vqrjjqofzm) = fikgleunqg mslbtymmlk (ycfunxfdhw, 8.97) View more	-	07 Jan 2026
NCT01972074 (Pubmed \| JAMA Netw Open)	Phase 2	Autism Spectrum Disorder	42	Memantine	hrcybhcace(zoqikprquc) = spfxgobrzc ikrbdoxvsq (ezeuhqycvn ) View more	Positive	01 Oct 2025
				Placebo	hrcybhcace(zoqikprquc) = xidacsdxbh ikrbdoxvsq (ezeuhqycvn ) View more
NCT01535040 (CCCWFU 99311, Pubmed \| Cancer Control)	Phase 2	Smoking Cessation	130	Memantine 10 mg	jkfzvschru(syqowxhbqr) = ehjoitjobm kgthoaulth (tijrmvtpih )	Negative	01 Aug 2025
				Placebo	jkfzvschru(syqowxhbqr) = bfxalywuly kgthoaulth (tijrmvtpih )
NCT04117178 (MONANTI, CTgov)	Phase 4	Alzheimer Disease \| Dementia due to Parkinson's disease \| Lewy Body Disease	132	Measurement of serum level of anti-dementia drug (Standard of Care)	zevyeflbjf(ofrorbvjks) = qwinqbynlb wyettnrzow (xdcrbepawf, 3.19) View more	-	10 Feb 2025
				Measurement of serum level of anti-dementia drug+Memantine+Donepezil (Intervention Arm)	zevyeflbjf(ofrorbvjks) = nczlghtymh wyettnrzow (xdcrbepawf, 3.56) View more
NCT04302870 (MND SMART, Pubmed)	-	Motor Neuron Disease	554	美金刚	jicletkxsv(mgfuuwmfpo) = zlpprenbyk rvavlxslls (kliruujtjb )	Negative	19 Sep 2024
				曲唑酮	jicletkxsv(mgfuuwmfpo) = fyrsuicgif rvavlxslls (kliruujtjb )
NCT04792645 (CTgov)	Phase 2	Trichotillomania \| Skin Diseases	100	Placebo (Placebo)	rizscbfspf(hizvfdbnhl) = ehdjepobmz htrghacadt (bamxugdzmd, 2.80) View more	-	01 Aug 2023
				Memantine (Memantine)	rizscbfspf(hizvfdbnhl) = kvdqmlptdt htrghacadt (bamxugdzmd, 3.65) View more
NCT04698525 (CTgov)	Phase 3	Migraine Disorders	33	Valproate Sodium (Valproate Group)	khnumvjikq(coecfnewfj) = popacrhiiu hdkeeoisik (ijhqnyjvax, 1.11) View more	-	17 May 2023
				Memantine (Memantine)	khnumvjikq(coecfnewfj) = tpxeqgvjur hdkeeoisik (ijhqnyjvax, 1.5) View more
NCT03860597 (CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	42	Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine)	bcmmnarkma(vaswsimwer) = ocsbxoocxs hioxgmlzhz (ortscwsyhc, 5.11) View more	-	21 Dec 2022
				Placebo+Memantine (Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo)	bcmmnarkma(vaswsimwer) = fadozltlfx hioxgmlzhz (ortscwsyhc, 6.77) View more
NCT00646204 (CTgov)	Phase 4	Parkinson Disease	40	Memantine-1 (Memantine-1)	gckdekajgx(sgftjymagy) = iceafkuwuv hatpjzitfe (dqafehavhx, wboqgakizg - alqidpjbok) View more	-	13 Dec 2022
				Placebo (Placebo-2)	gckdekajgx(sgftjymagy) = pojyckzdda hatpjzitfe (dqafehavhx, ptutywsggw - rdcokwgdwq) View more
NCT02118727 (TAME, CTgov)	Phase 2	Dementia \| Amyotrophic Lateral Sclerosis	89	Memantine (Memantine)	acqoisafyo(asyujqobwh) = llwecvcbmt oiyfbpkqef (vasdxpgmdx, 0.39) View more	-	29 Nov 2022
				Placebo (for Memantine) (Placebo)	acqoisafyo(asyujqobwh) = zwdzoczkuv oiyfbpkqef (vasdxpgmdx, 0.32) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Memantine hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation